1289 related articles for article (PubMed ID: 21647867)
1. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
[TBL] [Abstract][Full Text] [Related]
2. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry.
Schipper LG; Vermeer M; Kuper HH; Hoekstra MO; Haagsma CJ; Den Broeder AA; van Riel P; Fransen J; van de Laar MA
Ann Rheum Dis; 2012 Jun; 71(6):845-50. PubMed ID: 22210852
[TBL] [Abstract][Full Text] [Related]
3. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
Aletaha D; Smolen JS
Arthritis Rheum; 2011 Dec; 63(12):3702-11. PubMed ID: 21953215
[TBL] [Abstract][Full Text] [Related]
4. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
Sesin CA; Bingham CO
Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
[TBL] [Abstract][Full Text] [Related]
5. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.
Klarenbeek NB; Koevoets R; van der Heijde DM; Gerards AH; Ten Wolde S; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2011 Oct; 70(10):1815-21. PubMed ID: 21813548
[TBL] [Abstract][Full Text] [Related]
6. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort.
Vermeer M; Kuper HH; Moens HJ; Drossaers-Bakker KW; van der Bijl AE; van Riel PL; van de Laar MA
Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1219-26. PubMed ID: 23436821
[TBL] [Abstract][Full Text] [Related]
7. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
8. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
[TBL] [Abstract][Full Text] [Related]
9. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
de Punder YM; Fransen J; Kievit W; Houtman PM; Visser H; van de Laar MA; van Riel PL
Rheumatology (Oxford); 2012 Sep; 51(9):1610-7. PubMed ID: 22539487
[TBL] [Abstract][Full Text] [Related]
11. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study.
Urata Y; Uesato R; Tanaka D; Nakamura Y; Motomura S
Ann Rheum Dis; 2012 Apr; 71(4):534-40. PubMed ID: 22021897
[TBL] [Abstract][Full Text] [Related]
12. Remission in early rheumatoid arthritis -- a comparison of new ACR/EULAR remission criteria to established criteria.
Kuriya B; Sun Y; Boire G; Haraoui B; Hitchon C; Pope JE; Thorne JC; Keystone EC; Bykerk VP;
J Rheumatol; 2012 Jun; 39(6):1155-8. PubMed ID: 22505708
[TBL] [Abstract][Full Text] [Related]
13. Absent "Window of Opportunity" in smokers with short disease duration. Data from BARFOT, a multicenter study of early rheumatoid arthritis.
Söderlin MK; Bergman S;
J Rheumatol; 2011 Oct; 38(10):2160-8. PubMed ID: 21807778
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.
Combe B; Logeart I; Belkacemi MC; Dadoun S; Schaeverbeke T; Daurès JP; Dougados M
Ann Rheum Dis; 2015 Apr; 74(4):724-9. PubMed ID: 24399234
[TBL] [Abstract][Full Text] [Related]
15. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
[TBL] [Abstract][Full Text] [Related]
17. Treat-to-target approach in daily clinical practice in Pakistani patients with early Rheumatoid Arthritis.
Farman S; Ahmad NM; Saeed MA; Asad K; Shabbir G
J Coll Physicians Surg Pak; 2015 Feb; 25(2):129-33. PubMed ID: 25703758
[TBL] [Abstract][Full Text] [Related]
18. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.
van Tuyl LH; Lems WF; Voskuyl AE; Kerstens PJ; Garnero P; Dijkmans BA; Boers M
Ann Rheum Dis; 2008 Nov; 67(11):1574-7. PubMed ID: 18625629
[TBL] [Abstract][Full Text] [Related]
19. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
Kristensen LE; Kapetanovic MC; Gülfe A; Söderlin M; Saxne T; Geborek P
Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
[TBL] [Abstract][Full Text] [Related]
20. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
